Biosciences
Definition
The application of biological sciences to develop products, processes, and services across sectors including pharmaceuticals, biotechnology, medical devices, agricultural technology, and environmental science. Biosciences companies are among the most intangible-asset-intensive businesses in the global economy, with value concentrated in patents, regulatory approvals, clinical trial data, proprietary compounds, and specialised human capital. The valuation of bioscience intangible assets requires specialist knowledge of drug development pipelines, probability-weighted expected returns, patent cliff analysis, and regulatory pathway assessment. In purchase price allocations following bioscience acquisitions, in-process research and development (IPR&D) often represents the single largest identified intangible asset, valued using the multi-period excess earnings method (MPEEM) with risk adjustments reflecting clinical and regulatory uncertainty.
Complementary Terms
Concepts that frequently appear alongside Biosciences in practice.
Government-granted exclusive rights to an invention, giving the patent holder the right to prevent others from making, using, or selling the invention for a specified period (typically 20 years). Patents are among the most clearly defined and legally enforceable intangible assets.
The sharp decline in revenue experienced by a pharmaceutical or technology company when patent protection expires on a key product, exposing it to generic or competitive alternatives. Patent cliffs are a critical consideration in the valuation of patent-dependent businesses, as revenue can decline 70-90% within 12-24 months of patent expiry in the pharmaceutical sector.
Systematic investigation and experimentation aimed at creating new products, services, or processes, or significantly improving existing ones. R&D expenditure is one of the largest categories of intangible asset investment and is a key driver of innovation capital and future competitiveness.
The authorisation granted by a government or regulatory body permitting a company to manufacture, market, or sell a product or service in a specific jurisdiction. Regulatory approvals — including drug approvals (FDA, EMA), financial service licences (FCA, MAS), telecommunications licences, and environmental permits — are recognised as contract-based intangible assets in purchase price allocations under IFRS 3 and ASC 805 when they arise from contractual or legal rights.
The regulatory process by which a pharmaceutical product receives authorisation for commercial sale, granted by agencies such as the FDA (US), EMA (EU), and MHRA (UK). Drug approval requires demonstration of safety, efficacy, and manufacturing quality through preclinical studies and clinical trials.
The regulatory categorisation system that assigns medical devices to classes based on their risk to patients, which determines the level of regulatory scrutiny required for market approval. The EU MDR uses four classes (I, IIa, IIb, III) while the FDA uses three (I, II, III).
Put this knowledge to work
Use Opagio's free tools to measure and grow the intangible assets that drive your business value.